NOTCH4

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) resistance is a significant hurdle in lung adenocarcinoma (LUAD) treatment.
• Understanding resistance mechanisms is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the role of NOTCH4 mutations in EGFR-TKI resistance in LUAD.
• To identify potential therapeutic targets for overcoming EGFR-TKI resistance.

Main Methods:

• Analysis of NOTCH4 mutations in EGFR-TKI-sensitive and resistant LUAD patients.
• Functional studies involving exogenous induction of NOTCH4 mutations in LUAD cells.
• Investigation of the NOTCH4-HES1 signaling pathway and its interaction with p-STAT3.
• Inhibition of the NOTCH4-HES1 pathway using pharmacological inhibitors and small interfering RNAs (siRNAs).

Main Results:

• An increased frequency of the NOTCH4 L12_16 deletion mutation (NOTCH4ΔL12_16) was observed in EGFR-TKI-sensitive LUAD patients.
• Exogenous expression of NOTCH4ΔL12_16 sensitized EGFR-TKI-resistant LUAD cells to EGFR-TKIs.
• The NOTCH4ΔL12_16 mutation reduces intracellular NOTCH4 (NICD4), leading to decreased HES1 expression via altered promoter binding with p-STAT3.
• Inhibition of the NOTCH4-HES1 pathway reversed EGFR-TKI resistance in LUAD cells.

Conclusions:

• The NOTCH4ΔL12_16 mutation sensitizes LUAD to EGFR-TKIs by down-regulating HES1 expression.
• Targeting the NOTCH4-HES1 pathway presents a potential strategy to overcome EGFR-TKI resistance in LUAD.
• This finding offers a novel therapeutic approach for managing LUAD patients resistant to EGFR-TKI therapy.